A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection

BioWest Therapeutics

Status and phase: Completed; Phase 2

Conditions: Hepatitis C, Chronic

Treatments: Drug: Celgosivir

Study type: Interventional

Funder types: Industry

Identifiers

NCT00157534

HCV-04-001

Details and patient eligibility

About

The objective of the study is to evaluate the safety and efficacy of celgosivir for 12 weeks in patients with chronic hepatitis C genotype 1 infection.

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The patient must be 18 to 65 years of age, inclusive.
• Primary diagnosis of chronic HCV infection.

Exclusion criteria

• Patients who did not respond or relapsed following therapy with interferon.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)